Search

Research

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global mortality, often associated with high blood levels of LDL cholesterol (LDL-c). Medications like statins and PCSK9 inhibitors, are used to manage LDL-c levels and reduce ASCVD risk. Recent findings connect the gut microbiota and its metabolites to ASCVD development.

Community involvement

One way the Wal-yan Respiratory Research Centre provides the opportunity for consumers and community members to contribute to our research is through participation in one of our eight community reference groups.

News & Events

Winners Announced: 2021 Inspiration Awards

MEDIA ENQUIRIES Media Contacts About the Wal-yan Respiratory Research Centre Please direct general enquiries to our reception on (08) 6319 1000. Please direct media enquiries to our media team: Hayley Goddard Communications Specialist, Wal-yan

News & Events

20-year MAVRIC study celebrates recruitment of its 1000th participant

The MAVRIC (Mechanisms of Acute Viral Respiratory Infection in Children) study recently celebrated the recruitment of the 1000th participant to the study, eight-year-old Sullivan Strahan.

News & Events

Vertex grants to support advances in cystic fibrosis care

Two outstanding researchers from the Wal-yan Respiratory Research Centre have been awarded Vertex Cystic Fibrosis (CF) Mentored Innovation Research Awards.